Листи — звернення до медичних та фармацевтичних працівників – Сторінка 14

ГІЛЕНІЯ

20.03.2017 3419

Пам'ятка для лікаря щодо застосування фінголімоду при розсіяному склерозі: рекомендації з відбору пацієнтів, початкового обстеження (ЕКГ, аналізи), моніторингу першої дози та застереження щодо супутніх препаратів і серцево-судинних ризиків. складено автоматично

Erivedge®

01.07.2016 4225

Information material for healthcare professionals on the risks of embryotoxic and teratogenic effects of vismodegib (Erivedge®), including intrauterine fetal death and severe birth defects. Contains contraindications regarding pregnancy and breastfeeding, requirements for pregnancy testing and contraception, and an algorithm of actions in the event of pregnancy. generated automatically

Jardiance®

16.06.2016 6167

Information letter to health care professionals on updated data on the risk of diabetic ketoacidosis with the use of SGLT2 inhibitors. Contains recommendations for physicians on risk factors, symptoms, temporary treatment discontinuation and the procedure for reporting adverse reactions. generated automatically

Erivedge®

08.06.2016 4543

Information letter to healthcare professionals on the risk of premature fusion of the epiphyses (growth plates) with the use of a medicinal product containing the active substance vismodegib in pediatric practice. Contains a description of recorded cases, preclinical study data, recommendations, and measures for updating the instruction for medical use. generated automatically

Bioparox®

19.04.2016 6162

Informational letter to healthcare professionals on the withdrawal from the pharmaceutical market of medicinal products with the active substance fusafungine due to an unfavorable benefit/risk ratio and the EMA decision to revoke their marketing authorization. Contains recommendations on informing patients and the procedure for reporting adverse reactions. generated automatically

Tasigna (nilotinib)

28.03.2016 5119

Information letter addressed to healthcare professionals on the need to test patients for hepatitis B virus carriage before starting treatment with BCR-ABL tyrosine kinase inhibitors because of the risk of hepatitis B reactivation. Contains recommendations on screening, monitoring and the procedure for reporting adverse reactions. compiled automatically

Glivec (imatinib)

28.03.2016 4661

Informational letter to healthcare professionals on the need to screen patients for hepatitis B virus carriage before and during treatment with BCR-ABL tyrosine kinase inhibitors due to the risk of hepatitis B reactivation. Contains recommendations on testing, consultations, and the procedure for reporting adverse reactions. generated automatically

Tarceva (erlotinib)

04.02.2016 4401

Informational letter to healthcare professionals on the results of the TUNO study, which showed that the benefit/risk ratio of erlotinib as maintenance therapy in patients with non-small cell lung cancer without an EGFR-activating mutation is no longer considered favorable. The package insert for the medicine will be updated. generated automatically